Stockreport

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

TriSalus Life Sciences, Inc.  (TLSI) 
PDF Q4 Revenue of approximately $8.3 million represents approximately 44% growth versus Q4 2023Full year 2024 Revenue of approximately $29.4 million represent approximately [Read more]